Evidence map›Paper›PMID 26610340›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2016

Assessment of microscopic and molecular tools for the diagnosis and follow-up of cryptosporidiosis in patients at risk.

Y Le Govic, K Guyot, G Certad, A Deschildre, R Novo, C Mary, B Sendid, E Viscogliosi, L Favennec, E Dei-Cas and 3 more

Abstract readComparative StudyEvaluation Study
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Y Le GovicLaboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille, Université de Lille, Villeneuve-d'Ascq, France.
K GuyotUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France.
G CertadUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France.
A DeschildreUnité de pneumologie-allergologie pédiatrique, pôle enfant, clinique de pédiatrie Jeanne de Flandre, CHRU de Lille, Université de Lille, Lille, France.
R NovoUnité de Néphrologie Pédiatrique, CHRU de Lille, Lille, France.
C MaryAix-Marseille Université, Faculté de Médecine, UMR MD3, et APHM, Laboratoire de Parasitologie-Mycologie, Hôpital de la Timone, Marseille, France.
B SendidLaboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille, Université de Lille, Villeneuve-d'Ascq, France.
E ViscogliosiUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France.
L FavennecLaboratoire de Parasitologie, EA 3800-IRIB, CHRU de Rouen, Rouen, France.
E Dei-CasLaboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille, Université de Lille, Villeneuve-d'Ascq, France.
E FréalleLaboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille, Université de Lille, Villeneuve-d'Ascq, France. emilie.frealle-2@univ-lille2.fr.
E DutoitLaboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille, Université de Lille, Villeneuve-d'Ascq, France.
ANOFEL Cryptosporidium National Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cryptosporidiosis is an important though underreported public health concern. Molecular tools might be helpful in improving its diagnosis. In this study, ZR Fecal DNA MiniPrep™ Kit (ZR) and NucliSens® easyMAG® (EM) were compared using four Cryptosporidium-seeded feces and 29 Cryptosporidium-positive stools. Thereafter, ZR was selected for prospective evaluation of Cryptosporidium detection by 18S rDNA and LAXER quantitative PCR (qPCR) in 69 stools from 56 patients after Cryptosporidium detection by glycerin, modified Ziehl-Neelsen (ZN) and auramine-phenol (AP) stainings. The combination of any of the two extraction methods with 18S qPCR yielded adequate detection of Cryptosporidium in seeded stools, but the ZR kit showed the best performance. All 29 Cryptosporidium-positive samples were positive with 18S qPCR, after both ZR and EM extraction. However, false-negative results were found with LAXER qPCR or nested PCR. Cryptosporidiosis was diagnosed in 7/56 patients. All the microscopic methods enabled the initial diagnosis, but Cryptosporidium was detected in 12, 13, and 14 samples from these seven patients after glycerin, ZN, and AP staining respectively. Among these samples, 14 and 12 were positive with 18S and LAXER qPCR respectively. In two patients, Cryptosporidium DNA loads were found to be correlated with clinical evolution. Although little known, glycerin is a sensitive method for the initial detection of Cryptosporidium. When combined with 18S qPCR, ZR extraction, which had not been evaluated so far for Cryptosporidium, was an accurate tool for detecting Cryptosporidium and estimating the oocyst shedding in the course of infection.

Indexed as

AdolescentAdultChildCryptosporidiosisCryptosporidiumDNA, ProtozoanDNA, RibosomalFalse Negative ReactionsFemaleHumansMaleMicroscopyMolecular Diagnostic TechniquesPolymerase Chain ReactionRNA, Ribosomal, 18SStaining and LabelingDNA, ProtozoanDNA, RibosomalRNA, Ribosomal, 18S

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.